Mallinckrodt extends CEO Siggi Olafsson's tenure 30 days through Feb 28 amid contract talks

Keenova Therapeutics plc

CEO Olafsson had given notice of resignation effective Jan 29, 2024; agreed to stay through Feb 28, 2024.
Extension includes $123,750 cash payment (target bonus for period) plus severance upon termination.
Company is negotiating new employment agreement; no assurance Olafsson will remain beyond Feb 28.
Reimbursement of legal/tax advisory fees for negotiations, subject to release if no new agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sigurdur (Siggi) Olafsson

President and Chief Executive Officer

Keenova Therapeutics plc

Effective: 2024-02-28
Filed: January 26, 2024, 6:59 PM ET

Mr. Olafsson had previously provided written notice of his intention to resign as an employee effective January 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sigurdur (Siggi) Olafsson resigned as President and Chief Executive Officer at Keenova Therapeutics plc.

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

Mr. Olafsson had previously provided written notice of his intention to resign as an employee effective January 29, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-24-006963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.